02.08.2023,
4594 Zeichen
Aachen, Germany and Tokyo, Japan (ots) - Grünenthal GmbH (CEO:
Gabriel Baertschi), a global, science-based, privately-owned
pharmaceutical company and Kyowa Kirin Co., Ltd., (TSE:4151,
President and CEO: Masashi Miyamoto, Kyowa Kirin), a Japan-based
global specialty pharmaceutical company, today announced the
successful completion of a deal to enter into a Joint Venture
Collaboration for Kyowa Kirin International's established medicines
portfolio.
* The Joint Venture Collaboration includes a portfolio of 13 brands
across six therapeutic areas, with the majority of revenue
resulting from pain management medicines
* The new enterprise will be branded as Grünenthal Meds. Grünenthal
owns a 51 percent majority share and intends to acquire the
remaining share at the beginning of 2026
The portfolio comprises 13 brands across six therapeutic areas
primarily focused on pain management, including Abstral® and PecFent®
for breakthrough cancer pain, Moventig® for opioid-induced
constipation, and Adcal-D3® for osteoporosis. All products will
continue to be marketed through affiliates in seven major European
countries and through a network of partners in various additional
territories worldwide.
"Grünenthal is a global leader in pain management. With the addition
of this strong portfolio, we will be able to help more patients who
suffer from various forms of pain," said Gabriel Baertschi, Chief
Executive Officer, Grünenthal.
"The established medicines portfolio has a proud history of
delivering life-changing value for patients. Today's announcement now
means even more patients, for many years to come, will continue to
benefit from the portfolio. We are enormously grateful and proud of
our colleagues who have worked tirelessly to make this Joint Venture
Collaboration a reality," said Jeremy Morgan, President, Kyowa Kirin
International.
Grünenthal owns a 51 percent majority share in the Joint Venture
Collaboration, while Kyowa Kirin owns a 49 percent share. Grünenthal
intends to fully acquire the remaining 49 percent share via
exercising an option at the beginning of 2026.
About Grünenthal Meds
As part of the Joint Venture Collaboration between Grünenthal GmbH
and Kyowa Kirin Co., Ltd., a new enterprise has been created to
market Kyowa Kirin International's established medicines portfolio,
which comprises 13 brands across six therapeutic areas. This
enterprise will be branded in all markets as Grünenthal Meds.
The portfolio includes medicines that deliver life-changing value for
hundreds of thousands of patients. The portfolio is available in
seven major European markets through affiliates and in various
additional territories worldwide through a network of partners. Key
products in the portfolio include Abstral® and PecFent® (Fentanyl)
for breakthrough cancer pain, Moventig® (Naloxegol) for
opioid-induced constipation and Adcal-D3® (calcium and vitamin D3)
for osteoporosis. Visit www.grunenthalmeds.com to find out more.
About Kyowa Kirin
Kyowa Kirin strives to create and deliver novel medicines with
life-changing value. As a Japan-based global specialty pharmaceutical
company with a more than 70-year heritage, we apply cutting-edge
science, including an expertise in antibody research and engineering,
to address the needs of patients and society across multiple
therapeutic areas including Nephrology, Oncology, Immunology/Allergy
and Neurology. Across our four regions – Japan, Asia Pacific, North
America and EMEA/International – we focus on our purpose, to make
people smile, and are united by our shared values of commitment to
life, teamwork, innovation, and integrity. You can learn more about
the business of Kyowa Kirin at:
https://www.kyowakirin.com/.
Kyowa Kirin International is a subsidiary of Kyowa Kirin Co., Ltd.
About Grünenthal
Grünenthal is a global leader in pain management and related
diseases. As a science-based, fully-integrated pharmaceutical
company, we have a long track record of bringing innovative
treatments and state-of-the-art technologies to patients worldwide.
Our purpose is to change lives for the better – and innovation is our
passion. We are focusing all of our activities and efforts on working
towards our vision of a world free of pain.
Grünenthal is headquartered in Aachen, Germany, and has affiliates in
28 countries across Europe, Latin America and the US. Our products
are available in more than 100 countries. In 2022, Grünenthal
employed around 4,400 people and achieved sales of € 1.7 bn.
More information: www.grunenthal.com and Grünenthal Report 2022/23
digital edition (grunenthal.com)
Digital press kit:
http://www.ots.at/pressemappe/DE118252/aom
BSN Podcasts
Christian Drastil: Wiener Börse Plausch
Wiener Börse Party #716: Marinomed-Update (wikifolio), Ex-IIA-Vorstände übernehmen Althan Quartier, 330 Mio. Ziegel und Only You
Aktien auf dem Radar:Rosenbauer, FACC, CA Immo, Austriacard Holdings AG, Warimpex, Amag, Porr, Lenzing, Wienerberger, Bawag, DO&CO, EVN, voestalpine, Addiko Bank, ams-Osram, Marinomed Biotech, Oberbank AG Stamm, Flughafen Wien, Kapsch TrafficCom, Agrana, Erste Group, Immofinanz, Österreichische Post, S Immo, Telekom Austria, Uniqa, VIG.
Rosinger Group
Die Rosinger Group ist einer der führenden Finanzkonzerne in Mitteleuropa und in den Geschäftsfeldern "Eigene Investments" sowie "hochspezialisierte Beratungsleistungen" aktiv. Mit bisher mehr als sechzig Börsenlistings und IPOs weltweit gehört die Rosinger Group auch an der Wiener Börse zu den maßgeblichen Playern.
>> Besuchen Sie 68 weitere Partner auf boerse-social.com/partner
Mehr aktuelle OTS-Meldungen HIER